SAAP 148
Alternative Names: SAAP-148Latest Information Update: 28 Feb 2023
At a glance
- Originator Amsterdam UMC; Leiden University
- Developer Madam Therapeutics
- Class Antibacterials; Peptide antibiotics; Skin disorder therapies
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Burn infections; Methicillin-resistant Staphylococcus aureus infections; Wound infections
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Atopic-dermatitis in Netherlands (Gel)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in Netherlands (Intranasal, Cream)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Burn-infections in Netherlands (Topical)